Likewise, whether other biomarkers (e.g., placenta-enriched molecules and sFlt-1/PlGF ratios) [40,41] can aid in identifying a higher risk of fetal growth restriction, low birth weight, and neonatal morbidity in fetuses between the 10th and 20th EFW percentile throughout gestation merits further investigation. The gene discussed is PGF; the disease is fetal growth restriction.